Danske Lægers Vaccinations Service

Gladsaxevej 376. 1., Søborg, 2860, Denmark

Virus Diseases – Respiratory Syncytial Virus

The site focuses on preventing severe RSV infection in adults. A pragmatic trial evaluates the Abrysvo vaccine for reducing hospitalizations.

Pragmatic randomized design
Assessment of hospitalization risk
Adults aged 18 years and older

Danske Lægers Vaccinations Service leads efforts to protect the adult population from serious respiratory disease outcomes.

Skin and Connective Tissue Diseases – Herpes Zoster

Research evaluates the impact of the recombinant shingles vaccine on cardiovascular health and cognitive decline. The study examines the Shingrix vaccine’s effect on major adverse cardiovascular events and new dementia cases.

Evaluation of cardiovascular outcomes
Investigation of dementia risk
Adults aged 65 years and older

This work highlights broader benefits of vaccination beyond infection control at Danske Lægers Vaccinations Service.

Evaluating the effect of recombinant varicella zoster virus glycoprotein E vaccine on heart problems and dementia in adults aged 65 years or older with herpes zoster

Recruiting

3 1 1 1
Investigated Diseases:
- Herpes zoster
Investigated Drugs:
- Recombinant Varicella Zoster Virus Glycoprotein E
Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

Not yet recruiting

3 1 1 1
Investigated Diseases:
- Respiratory syncytial virus infection
Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

Not yet recruiting

3 1 1 1
Investigated Drugs:
A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Not recruiting

3 1 1 1
Investigated Diseases:
- COVID-19
Investigated Drugs:
- Elasomeran
Study on the Effectiveness of RSV Vaccine (Abrysvo) in Preventing Hospitalizations in Adults Aged 60 and Older

Not recruiting

3 1 1 1
Investigated Diseases:
- Respiratory syncytial virus infection

Danske Lægers Vaccinations Service

Virus Diseases – Respiratory Syncytial Virus

Skin and Connective Tissue Diseases – Herpes Zoster

Evaluating the effect of recombinant varicella zoster virus glycoprotein E vaccine on heart problems and dementia in adults aged 65 years or older with herpes zoster

Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Study on the Effectiveness of RSV Vaccine (Abrysvo) in Preventing Hospitalizations in Adults Aged 60 and Older

We use cookies